CLADRIBINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H12ClN5O3
Molecular Weight	285.687
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC(Cl)=NC2=C1N=CN2[C@H]3C[C@H](O)[C@@H](CO)O3

InChI

InChIKey=PTOAARAWEBMLNO-KVQBGUIXSA-N

InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020229s034lbl.pdf
Curator's Comment: Description was created using several sources including: https://www.scripps.edu/newsandviews/e_20090601/MS.html; http://comtecmed.com/CONY/2008/Uploads/assets/speakers%20abstracts/stelmasiak.pdf

Cladribine is used for the treatment of hairy cell leukemia and multiple sclerosis (MS). As a purine analog, it is a synthetic anti-cancer agent that also suppresses the immune system. Chemically, it mimics the nucleoside adenosine and thus inhibits the enzyme adenosine deaminase, which interferes with the cell's ability to process DNA. It can be distinguished from other chemotherapeutic agents affecting purine metabolism in that it is cytotoxic to both actively dividing and quiescent lymphocytes and monocytes, inhibiting both DNA synthesis and repair. Cladribine injection is a potent antineoplastic agent with potentially significant toxic side effects. In MS, the novel mechanism of action of cladribine is expected to reduce inflammation, autoimmune effects and autoreactive cell damage, thereby improving the integrity of the blood–brain barrier. Thus, the effects of cladribine may target some of the key events that are central to the pathophysiology of MS.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA polymerase beta 5 Target ID: P06746 Gene ID: 5423.0 Gene Symbol: POLB Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=20634380	Inhibitor 8297
DNA 278 Target ID: CHEMBL2311221 Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=20634380	Binding Agent 1064
Adenosylhomocysteinase 5 Target ID: P23526 Gene ID: 191.0 Gene Symbol: AHCY Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=20634380	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hairy cell leukemia 2 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe	Primary		Approved 8429	CLADRIBINE Approved Use the treatment of active Hairy Cell Leukemia as defined by clinically significant anemia, neutropenia, thrombocytopenia or disease-related symptoms. Launch Date 1995

C_max

Value	Dose	Co-administered	Analyte	Population
20.57 ng/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022561Orig1s000ClinPharmR.pdf	3 mg single, intravenous dose: 3 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CLADRIBINE plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
29.05 ng/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022561Orig1s000ClinPharmR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		CLADRIBINE plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
69.4 ng × h/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022561Orig1s000ClinPharmR.pdf	3 mg single, intravenous dose: 3 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CLADRIBINE plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
99.17 ng × h/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022561Orig1s000ClinPharmR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		CLADRIBINE plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
18.4 h REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022561Orig1s000ClinPharmR.pdf	3 mg single, intravenous dose: 3 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CLADRIBINE plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
19.7 h REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022561Orig1s000ClinPharmR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		CLADRIBINE plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
5.25 mg/kg multiple, oral (total) Highest studied dose Dose: 5.25 mg/kg Route: oral Route: multiple Dose: 5.25 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/24502830 Page: p.262	unhealthy, ADULT n = 204 Health Status: unhealthy Condition: multiple sclerosis Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 204 Sources: https://pubmed.ncbi.nlm.nih.gov/24502830 Page: p.262	Disc. AE: Lymphopenia... AEs leading to discontinuation/dose reduction: Lymphopenia (grade 3-4) Sources: https://pubmed.ncbi.nlm.nih.gov/24502830 Page: p.262
8 mg/m2 1 times / day multiple, intravenous MTD Dose: 8 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 8 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7911736 Page: p.170	unhealthy, ADULT n = 4 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/7911736 Page: p.170	DLT: Neutropenia, Leukopenia... Dose limiting toxicities: Neutropenia (grade 4, 50%) Leukopenia (grade 4, 50%) Sources: https://pubmed.ncbi.nlm.nih.gov/7911736 Page: p.170
0.07 mg/kg 1 times / day multiple, subcutaneous Studied dose Dose: 0.07 mg/kg, 1 times / day Route: subcutaneous Route: multiple Dose: 0.07 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10720289 Page: p.1152	unhealthy, ADULT n = 52 Health Status: unhealthy Condition: multiple sclerosis Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 52 Sources: https://pubmed.ncbi.nlm.nih.gov/10720289 Page: p.1152	Sources: https://pubmed.ncbi.nlm.nih.gov/10720289 Page: p.1152

AEs

AE	Significance	Dose	Population
Lymphopenia	grade 3-4 Disc. AE	5.25 mg/kg multiple, oral (total) Highest studied dose Dose: 5.25 mg/kg Route: oral Route: multiple Dose: 5.25 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/24502830 Page: p.262	unhealthy, ADULT n = 204 Health Status: unhealthy Condition: multiple sclerosis Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 204 Sources: https://pubmed.ncbi.nlm.nih.gov/24502830 Page: p.262
Leukopenia	grade 4, 50% DLT	8 mg/m2 1 times / day multiple, intravenous MTD Dose: 8 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 8 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7911736 Page: p.170	unhealthy, ADULT n = 4 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/7911736 Page: p.170
Neutropenia	grade 4, 50% DLT	8 mg/m2 1 times / day multiple, intravenous MTD Dose: 8 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 8 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7911736 Page: p.170	unhealthy, ADULT n = 4 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/7911736 Page: p.170

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587 inducer 781	substrate 1037 inhibitor 1767	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2B6 810 CYP2C8 911 CYP2C19 1478 CYP2E1 882 P-gp 1461 BCRP 699 MRP2 383 MRP4 204 MRP5 22 OATP1B1 788 OATP1B3 706 OAT1 599 OAT3 642 OAT4 146 OCT1 512 OCT2 647	CYP2E1 667 BCRP 561 P-gp 1537 MRP4 77 OCT2 355 OAT1 326 OAT3 339 OAT4 78 CYP1A2 1054 CYP2A6 543 CYP2C19 991	CYP1A2 701 CYP2B6 547

Drug as perpetrator

Target	Modality	Activity
BCRP 773	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
CYP1A2 1692	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
CYP1A2 1692	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022561s000lbl.pdf	no
CYP2B6 1001	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
CYP2B6 1001	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022561s000lbl.pdf	no
CYP2C19 1553	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022561s000lbl.pdf	no
CYP2C8 965	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022561s000lbl.pdf	no
CYP2C9 1819	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022561s000lbl.pdf	no
CYP2D6 1891	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022561s000lbl.pdf	no
CYP2E1 970	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022561s000lbl.pdf	no
CYP3A4 1925	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
CYP3A4 1925	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022561s000lbl.pdf	no
MRP2 475	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
MRP4 238	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
MRP5 48	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
OAT1 603	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
OAT3 644	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
OAT4 146	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
OATP1B1 803	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
OATP1B3 715	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
OCT1 543	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
OCT2 648	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
P-gp 1650	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no

Drug as victim

Target	Modality	Activity
CYP1A2 1054	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
CYP2A6 543	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
CYP2C19 991	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
CYP2C9 1037	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
CYP2E1 667	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
CYP3A4 1737	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
MRP4 77	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
OAT1 326	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
OAT3 339	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
OAT4 78	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
OCT2 355	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/	no
BCRP 561	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022561s000lbl.pdf \| https://pubmed.ncbi.nlm.nih.gov/18765824/	yes
P-gp 1537	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022561s000lbl.pdf	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://pubmed.ncbi.nlm.nih.gov/29987837/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:567361	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:567361
MolPort	MolPort-002-054-532	https://www.molport.com/shop/molecule-link/MolPort-002-054-532
Selleck Chemicals	Cladribine	http://www.selleckchem.com/products/Cladribine.html
ZINC	ZINC000003798064	http://zinc15.docking.org/substances/ZINC000003798064
eMolecules	29542740	https://www.emolecules.com/cgi-bin/more?vid=29542740

PubMed

Title	Date	PubMed
[Nucleoside analogues--new drugs for the treatment of lymphatic cancers].	2001	12092367
[Lupus nephritis: treatments for today and tomorrow].	2001	11881420
Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.	2001	11845978
Infectious complications of purine analog therapy.	2001 Aug	11964857
Successful treatment of refractory Langerhans cell histiocytosis with unrelated cord blood transplantation.	2001 Dec	11902312
Cladribine. Ortho Biotech Inc.	2001 Dec	11892941
Hematological effects of intermittent 2-hour infusions of cladribine in multiple sclerosis patients: a comparison of 2 dosage patterns.	2001 Dec	11794698
Hairy cell leukemia.	2001 Jun	12057121
Gynecomastia in a case of hairy cell leukaemia--cladribine induced?	2001 Jun	11699216
Immunologic therapy for secondary and primary progressive multiple sclerosis.	2001 May	11898531
Prolymphocytic leukemia or prolymphocytic transformation of mantle cell lymphoma.	2001 Nov	11710698
Resistance to 2-chloro-2'-deoxyadenosine of the human B-cell leukemia cell line EHEB.	2001 Nov	11705877
Treatment of hairy-cell leukemia.	2001 Nov 15	11794207
Plasmablastic lymphoma in a patient with chronic lymphocytic leukemia heavily pretreated with cladribine (2-CdA): an unusual variant of Richter's syndrome.	2001 Nov-Dec	11872081
In vitro release of cytotoxic nucleoside analogs from lactide-caprolactone and lactide-glycolide copolymers.	2002	12136942
5'-Esters of 2'-deoxyadenosine and 2-chloro-2'-deoxyadenosine with cell differentiation-provoking agents.	2002	12136933
Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials.	2002	12102646
Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia.	2002	12097998
Immunosuppression with limited toxicity: the characteristics of nucleoside analogs and anti-lymphocyte antibodies used in non-myeloablative hematopoietic cell transplantation.	2002	11908199
Gateways to Clinical Trials.	2002 Apr	12087878
The role of mitoxantrone in non-Hodgkin's lymphoma.	2002 Apr	12017536
Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.	2002 Apr	11948108
[Hairy cell leukemia treated with cladribine].	2002 Apr 30	12043051
Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma: a frequent association?	2002 Aug	12145685
Specificity of human and rat orthologs of the concentrative nucleoside transporter, SPNT.	2002 Aug	12110519
Induction of apoptosis by cladribine (2-CdA), gemcitabine and other chemotherapeutic drugs on CD34+/CD38+ and CD34+/CD38- hematopoietic progenitor cells: selective effects of doxorubicin and 2-CdA with protection of immature cells.	2002 Feb	11999573
Cladribine underdosing in hairy-cell leukemia: a cause for apparent response failure.	2002 Feb	11999571
Fludarabine therapy in Waldenström's macroglobulinemia patients treated previously with 2-chlorodeoxyadenosine.	2002 Feb	11999570
Therapeutic approaches to secondary progressive multiple sclerosis.	2002 Feb	11936495
Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin.	2002 Feb	11859396
Radiation therapy and combination of cladribine, cyclophosphamide, and prednisone as treatment of Bing-Neel syndrome: Case report and review of the literature.	2002 Feb	11835349
Use of 2-chlorodeoxyadenosine to treat infantile myofibromatosis.	2002 Jan	11902743
2-Chloro-2'-deoxyadenosine inhibits DNA repair synthesis and potentiates UVC cytotoxicity in chronic lymphocytic leukemia B lymphocytes.	2002 Jan	11840261
Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases.	2002 Jan	11801472
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.	2002 Jan	11801463
Resistance of leukemic cells to 2-chlorodeoxyadenosine is due to a lack of calcium-dependent cytochrome c release.	2002 Jan 15	11781251
Exposure-disease continuum for 2-chloro-2'-deoxyadenosine (2-CdA), a prototype teratogen: induction of lumbar hernia in the rat and species comparison for the teratogenic responses.	2002 Jul	12115775
Immune response by host after allogeneic chondrocyte transplant to the cartilage.	2002 Jul 1	12112416
Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine.	2002 Jun	12100691
Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.	2002 Jun	12040435
Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia.	2002 Jun	12040433
Widespread skin-limited adult Langerhans cell histiocytosis: long-term follow-up with good response to interferon alpha.	2002 Mar	11952707
Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine.	2002 Mar	11891804
Severe decrease in peripheral blood dendritic cells in hairy cell leukaemia.	2002 Mar	11849216
Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients.	2002 Mar	11849209
Cytotoxicity of 2-chlorodeoxyadenosine and arabinosylcytosine in leukaemic lymphoblasts from paediatric patients: significance of cellular nucleoside transporter content.	2002 Mar	11849208
[Therapeutic effectiveness of cladribine and cellular immunodeficiency--related effects in hairy-cell leukemia?].	2002 May	12061204
Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues.	2002 May	11994981
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.	2002 Sep	12127565
Adenine and deazaadenine nucleoside and deoxynucleoside analogues: inhibition of viral replication of sheep MVV (in vitro model for HIV) and bovine BHV-1.	2002 Sep	12110319

Patents

Sample Use Guides

In Vivo Use Guide

0.09 mg/kg/day

Route of Administration: Intravenous

In Vitro Use Guide

0.05 - 0.4 uM

Name

Type

Language

CLADRIBINE

Official Name

English

CLADRIBINE [HSDB]

Common Name

English

CLADRIBINE [EP MONOGRAPH]

Common Name

English

MAVENCLAD

Common Name

English

2-CHLORODEOXYADENOSINE

Systematic Name

English

2-CDA

Common Name

English

CLADRIBINE [USP MONOGRAPH]

Common Name

English

CLADRIBINE [USP-RS]

Common Name

English

LITAK

Brand Name

English

cladribine [INN]

Common Name

English

CLADRIBINE [MART.]

Common Name

English

Cladribine [WHO-DD]

Common Name

English

ADENOSINE, 2-CHLORO-2'-DEOXY-

Systematic Name

English

2-CHLORO-2'-DEOXYADENOSINE

Systematic Name

English

CLADRIBINE [ORANGE BOOK]

Common Name

English

NSC-105014

Code

English

CLADRIBINE [EMA EPAR]

Common Name

English

LEUSTATIN

Brand Name

English

CLADRIBINE [MI]

Common Name

English

CLADRIBINE [VANDF]

Common Name

English

CLADRIBINE [JAN]

Common Name

English

RWJ-26251

Code

English

CLADRIBINE [USP IMPURITY]

Common Name

English

CLADRIBINE [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2157